JP2010508306A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010508306A5 JP2010508306A5 JP2009534946A JP2009534946A JP2010508306A5 JP 2010508306 A5 JP2010508306 A5 JP 2010508306A5 JP 2009534946 A JP2009534946 A JP 2009534946A JP 2009534946 A JP2009534946 A JP 2009534946A JP 2010508306 A5 JP2010508306 A5 JP 2010508306A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- pai
- agent
- weight
- combinations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 33
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 claims description 22
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims description 22
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 14
- 208000010412 Glaucoma Diseases 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- -1 WAY-140312 Chemical compound 0.000 claims description 8
- 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 claims description 4
- ODXQFEWQSHNQNI-UHFFFAOYSA-N Tiplasinin Chemical compound C12=CC=C(C=3C=CC(OC(F)(F)F)=CC=3)C=C2C(C(=O)C(=O)O)=CN1CC1=CC=CC=C1 ODXQFEWQSHNQNI-UHFFFAOYSA-N 0.000 claims description 4
- 102100035140 Vitronectin Human genes 0.000 claims description 4
- 108010031318 Vitronectin Proteins 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 4
- 239000002585 base Substances 0.000 claims description 4
- 239000002876 beta blocker Substances 0.000 claims description 4
- 229940097320 beta blocking agent Drugs 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 4
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 claims description 4
- 239000003623 enhancer Substances 0.000 claims description 4
- 239000003349 gelling agent Substances 0.000 claims description 4
- 230000002209 hydrophobic effect Effects 0.000 claims description 4
- 239000003604 miotic agent Substances 0.000 claims description 4
- 239000004090 neuroprotective agent Substances 0.000 claims description 4
- 239000003961 penetration enhancing agent Substances 0.000 claims description 4
- 239000000816 peptidomimetic Substances 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- 150000003180 prostaglandins Chemical class 0.000 claims description 4
- 239000003590 rho kinase inhibitor Substances 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 239000003981 vehicle Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 206010030043 Ocular hypertension Diseases 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 210000001585 trabecular meshwork Anatomy 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 208000022873 Ocular disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 15
- 208000030533 eye disease Diseases 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86371506P | 2006-10-31 | 2006-10-31 | |
| PCT/US2007/083170 WO2008055205A2 (en) | 2006-10-31 | 2007-10-31 | Pai-1 binding modulators for the treatment of ocular disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010508306A JP2010508306A (ja) | 2010-03-18 |
| JP2010508306A5 true JP2010508306A5 (enExample) | 2011-06-30 |
Family
ID=39345074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009534946A Pending JP2010508306A (ja) | 2006-10-31 | 2007-10-31 | 眼障害を治療するためのｐａｉ−１結合調節因子 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20080107644A1 (enExample) |
| EP (1) | EP2077829A2 (enExample) |
| JP (1) | JP2010508306A (enExample) |
| KR (1) | KR20090082401A (enExample) |
| CN (1) | CN101588798A (enExample) |
| AU (1) | AU2007313684A1 (enExample) |
| CA (1) | CA2666316A1 (enExample) |
| MX (1) | MX2009004792A (enExample) |
| RU (1) | RU2465898C2 (enExample) |
| WO (1) | WO2008055205A2 (enExample) |
| ZA (1) | ZA200902453B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100158897A1 (en) * | 2006-10-31 | 2010-06-24 | Alcon Research, Ltd. | Pai-1 modulators for the treatment of ocular disorders |
| US20090202524A1 (en) * | 2007-10-31 | 2009-08-13 | Alcon Research, Ltd. | Pai-1 expression and activity inhibitors for the treatment of ocular disorders |
| EP2790023B1 (en) | 2011-11-15 | 2018-07-04 | National University Corporation Hamamatsu University School of Medicine | Therapeutic and diagnostic agent for early delivery or abortion using plasminogen activator inhibitor-1 |
| US10946076B2 (en) | 2013-02-13 | 2021-03-16 | The Research Foundation For The State University Of New York | Glaucoma treatment |
| US9820954B2 (en) * | 2015-08-19 | 2017-11-21 | Jenivision Inc. | Quantitative peri-orbital application of ophthalmology drugs |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993024121A1 (fr) * | 1992-05-22 | 1993-12-09 | Senju Pharmaceutical Co., Ltd. | Medicament pour le glaucome |
| AR002194A1 (es) * | 1997-03-17 | 1998-01-07 | Sanchez Reynaldo Alemany | Instrumento computarizado para el analisis del movimiento. |
| WO2000035439A1 (en) * | 1998-12-11 | 2000-06-22 | Bakulesh Mafatlal Khamar | The process for manufacturing formulation of topical beta blockers with improved efficacy |
| CA2358400C (en) * | 1999-01-05 | 2012-05-15 | Nancy A. Noble | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
| CA2476761A1 (en) * | 2002-02-19 | 2003-08-28 | Vanderbilt University | Therapeutic methods employing pai-1 inhibitors and transgenic non-human animal for screening candidate pai-1 inhibitors |
| KR20040104566A (ko) * | 2002-04-30 | 2004-12-10 | 알콘, 인코퍼레이티드 | 안압 저하 및 녹내장성 망막병증/시신경병증 치료를 위한특유의 수단으로서의 결합 조직 성장 인자 (ｃｔｇｆ)의활성 및/또는 발현 조절, 저해, 또는 변조제 |
-
2007
- 2007-10-31 AU AU2007313684A patent/AU2007313684A1/en not_active Abandoned
- 2007-10-31 US US11/931,393 patent/US20080107644A1/en not_active Abandoned
- 2007-10-31 CA CA002666316A patent/CA2666316A1/en not_active Abandoned
- 2007-10-31 MX MX2009004792A patent/MX2009004792A/es not_active Application Discontinuation
- 2007-10-31 WO PCT/US2007/083170 patent/WO2008055205A2/en not_active Ceased
- 2007-10-31 CN CNA2007800407976A patent/CN101588798A/zh active Pending
- 2007-10-31 ZA ZA200902453A patent/ZA200902453B/xx unknown
- 2007-10-31 RU RU2009120545/15A patent/RU2465898C2/ru not_active IP Right Cessation
- 2007-10-31 KR KR1020097010021A patent/KR20090082401A/ko not_active Withdrawn
- 2007-10-31 EP EP07868631A patent/EP2077829A2/en not_active Withdrawn
- 2007-10-31 JP JP2009534946A patent/JP2010508306A/ja active Pending
-
2010
- 2010-06-25 US US12/823,773 patent/US20100260784A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4934653B2 (ja) | Ｒｈｏキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤 | |
| JP4968954B2 (ja) | 活性成分、ポロキサマー界面活性剤もしくはメロキサポール界面活性剤およびグリコールを含有する懸濁処方物、ならびに眼の障害を処置するための医薬の製造のためのその使用 | |
| CN1684689A (zh) | 由Rho激酶抑制剂和前列腺素类物质构成的青光眼治疗剂 | |
| AU2011282681B2 (en) | Preservative free bimatoprost and timolol solutions | |
| RU2009149687A (ru) | Фармацевтические композиции и способы лечения сухих кератитов | |
| WO2019236148A1 (en) | Low-dose brimonidine combinations and uses thereof | |
| JP2021152008A (ja) | ２，４，６−トリフルオロ−ｎ−［６−（１−メチル−ピペリジン−４−カルボニル）−ピリジン−２−イル］−ベンズアミドの組成物 | |
| US20140249153A1 (en) | Fixed dose combination of bimatoprost and brimonidine | |
| JP2021102626A (ja) | ブリモニジン及びチモロールの固定用量合剤 | |
| JP2010508306A5 (enExample) | ||
| JP4482726B2 (ja) | Ｒｈｏキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤 | |
| TW202031263A (zh) | 抑制軟性隱形眼鏡變質之眼科用組成物 | |
| JP4968955B2 (ja) | 眼用薬物、ポロキサミンおよびグリコール張度調整剤を含有する眼用懸濁液、ならびに眼の障害を処置するための医薬の製造のためのこの組成物の使用 | |
| US7005448B2 (en) | Aminoalkyl-benzofuran-5-ol compounds for the treatment of glaucoma | |
| JP4849288B2 (ja) | 点眼剤及び涙液膜の安定化剤 | |
| RU2009120545A (ru) | Модуляторы связывания pai-1 для лечения глазных болезней | |
| JP2011518828A5 (enExample) | ||
| CN111526876A (zh) | 含有吡啶基氨基乙酸化合物的药物制剂 | |
| JP2012250951A (ja) | アデノシン誘導体とプロスタグランジン類とβ受容体遮断薬の組合せ剤 | |
| JP4300347B2 (ja) | ブナゾシンとプロスタグランジン類からなる緑内障治療剤 | |
| JP2012006962A (ja) | 眼科用組成物 | |
| EP3730137B1 (en) | Therapeutic agent for glaucoma comprising an fp agonist and timolol | |
| US20210369706A1 (en) | Low-dose brimonidine combinations and uses thereof | |
| JP5560588B2 (ja) | 眼科用剤 | |
| US20060211700A1 (en) | (R)-8,9-dichloro-2,3,4,4a-tetrahydro-1H,6H-pyrazino[1,2-a]quinoxalin-5-one for controlling IOP and treating glaucoma |